Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other financing activities (2020 - 2025)

Bioventus' Other financing activities history spans 6 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Other financing activities rose 778.35% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $697000.0, up 191.95%, while the annual FY2025 figure was $697000.0, 191.95% up from the prior year.
  • Other financing activities reached $1.3 million in Q4 2025 per BVS's latest filing, up from -$207000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.0 million in Q4 2023 to a low of -$376000.0 in Q4 2021.
  • Average Other financing activities over 5 years is $159050.0, with a median of -$83000.0 recorded in 2023.
  • The largest YoY upside for Other financing activities was 36418.18% in 2023 against a maximum downside of 983.33% in 2023.
  • A 5-year view of Other financing activities shows it stood at -$376000.0 in 2021, then soared by 97.07% to -$11000.0 in 2022, then soared by 36418.18% to $4.0 million in 2023, then plummeted by 104.86% to -$194000.0 in 2024, then soared by 778.35% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Other financing activities are $1.3 million (Q4 2025), -$207000.0 (Q3 2025), and -$209000.0 (Q2 2025).